Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials

Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic

To see complete record on, please visit this link

Id: NCT05243329

Organisation Name: Halucenex Life Sciences Inc.

Overal Status: Active, not recruiting

Start Date: October 3, 2022

Last Update: January 10, 2023

Lead Sponsor: Halucenex Life Sciences Inc.

Brief Summary: Post-traumatic stress disorder (PTSD) is a complex disorder expressed as a variety of neurobiological symptoms, including anxiety, re-experiencing, hyperarousal, and avoidance symptoms, along with comorbidities such as anxiety, depression, and increased risk for self-medicating substance abuse. Currently, there are only two approved medications in the United States (US) for PTSD, paroxetine and sertraline.

Psychedelic medications, including psilocybin, have recently received breakthrough designation by the US Food and Drug Administration (FDA) for other psychiatric indications. Although no formal clinical trials have yet investigated psychedelic substances for the treatment of PTSD, the available evidence warrants such an investigation. The present study aims to investigate the effect of psilocybin on treatment-resistant PTSD.

  • Treatment Resistant Disorders
  • Post Traumatic Stress Disorder

Total execution time in seconds: 0.29007577896118